Karande Mahesh 4
4 · Omega Therapeutics, Inc. · Filed Feb 3, 2022
Insider Transaction Report
Form 4
Karande Mahesh
DirectorPresident and CEO10% Owner
Transactions
- Exercise/Conversion
Common Stock
2022-02-01$0.53/sh+11,300$5,989→ 117,711 total - Exercise/Conversion
Option (Right to Buy)
2022-02-01−11,300→ 884,071 totalExercise: $0.53Exp: 2029-06-23→ Common Stock (11,300 underlying)
Footnotes (1)
- [F1]The options vest and become exercisable with respect to 25% of the underlying shares on April 1, 2020 and in equal quarterly installments thereafter such that the option will become fully vested and exercisable on April 1, 2023, subject to the Reporting Person's continued service to the Issuer through each vesting date.